HIMS LAWSUIT DEADLINE: Suffer Losses on Hims & Hers Health, Inc.? Contact BFA Law before the August 25 Securities Fraud Class Action Deadline (NYSE:HIMS)

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - Two complaints have been filed, with the first case titled Sookdeo v. Hims & Hers Health, Inc., and a subsequent similar complaint titled Yaghsizian v. Hims & Hers Health, Inc. [2]. Group 2: Allegations Against Hims & Hers - Hims & Hers operates a telehealth platform providing access to healthcare consultations and wellness products, and recently announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy [3]. - Allegations include misrepresentation of the partnership with Novo Nordisk, specifically regarding the sale of Wegovy and compounded semaglutide, and claims of compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' alleged deceptive practices, Hims & Hers' stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].